Here is your complete HTML news article on the Global Healthcare Forum in Anhui, designed for foreign executives evaluating China market opportunities.
“`html

Global Healthcare Forum to Be Held in Anhui: A Strategic Gateway for Foreign Investment

The Global Healthcare Forum (全球医疗论坛, Quánqiú Yīliáo Lùntán), scheduled for October 15–17, 2025 in Hefei, Anhui Province, is expected to convene more than 2,400 delegates from 45 countries, including healthcare executives, biotech innovators, and policy-makers. This high-level gathering marks Anhui’s most ambitious international push in the medical sector, aiming to position the province as a premier destination for healthcare R&D, manufacturing, and cross-border partnership in China. The forum will feature 60+ speakers, dedicated matchmaking sessions, and a showcase of Anhui’s rapidly expanding medical ecosystem.

Several figures underline the significance of this event for foreign decision-makers:

• ¥320 billion (≈ USD 44 billion) – Anhui’s total healthcare industry output in 2024, reflecting a 15.3% year-on-year increase and outpacing the national average by 4 percentage points.
• 500+ medical device and biopharmaceutical enterprises now operate in Anhui, including 58 foreign-invested firms from the US, Germany, Japan, and South Korea.
• ¥30 billion (≈ USD 4.1 billion) – Value of new healthcare infrastructure projects approved for Anhui in 2025 alone, spanning hospitals, innovation parks, and cold-chain logistics.
• 12% – Anhui’s share of China’s national output in Traditional Chinese Medicine (中医药, Zhōngyīyào), a sector the province is now integrating with modern biotech platforms.
• 8.2× growth in biotech patent filings (2019–2024), ranking Anhui 5th among all Chinese provinces for healthcare-related intellectual property activity.

1. Forum Overview and Strategic Significance

The Global Healthcare Forum is organized by the Anhui Provincial Department of Commerce in cooperation with the China National Medical Equipment Association and the Hefei Municipal Government. Its central theme — “Integration, Innovation, Access” — reflects Anhui’s ambition to bridge global medical technology with China’s clinical demand and manufacturing scale.

The three-day event will include four dedicated tracks: medical devices, biopharmaceuticals, digital health and AI diagnostics, and Traditional Chinese Medicine modernization. Each track features plenary sessions led by international experts, followed by closed-door B2B matchmaking with Anhui-based hospitals, distributors, and industrial park administrators. The forum is expected to facilitate ¥8 billion (≈ USD 1.1 billion) in signed memorandums and joint venture agreements.

For foreign companies evaluating a China entry or expansion, the forum offers a calibrated alternative to the larger, more saturated events in Shanghai or Beijing. Anhui’s government has committed to expedited licensing pathways for medical devices and drugs developed through partnerships formed at the forum, a tangible policy advantage that early movers can leverage.

Anhui’s geographic position — within a 3-hour high-speed rail radius of Shanghai, Nanjing, and Hangzhou — and its growing airport cargo capacity make it a logistical hub for both domestic distribution and export to Southeast Asia. At least 12 new direct international air routes connecting Hefei to Europe, the Middle East, and East Asia are scheduled to launch before the forum opens.

2. Anhui’s Healthcare Industry Landscape: Data-Driven Momentum

Foreign executives considering the forum need a clear picture of Anhui’s current healthcare ecosystem. The province ranks 8th nationally in total healthcare output, but its growth rate (15.3% in 2024) places it among the top three provinces. Unlike some coastal regions where healthcare expansion is reaching saturation, Anhui still offers significant room for greenfield investment and capacity building.

Two sectors stand out for foreign opportunity. Medical devices (医疗器械, Yīliáo Qìxiè) account for roughly 38% of Anhui’s healthcare output, with particular strength in imaging equipment, in-vitro diagnostics, and surgical robotics. Anhui is home to the China Medical Device Innovation Valley in Hefei, a 200-hectare park offering rent subsidies, tax holidays, and direct connections to 30+ hospitals for clinical validation. Meanwhile, the biopharmaceutical (生物医药, Shēngwù Yīyào) segment has grown 22% annually since 2021, driven by cell and gene therapy research anchored at the University of Science and Technology of China (USTC) and Anhui Medical University.

Another distinctive asset is Anhui’s Traditional Chinese Medicine (TCM) ecosystem. The province produces more than 200 authenticated TCM materials and has integrated TCM into 95% of its public hospitals. Foreign companies interested in botanical drugs or TCM-derived nutraceuticals can access a ready-made supply chain and a regulatory environment that now increasingly recognizes dual TCM-Western medicine product categories.

3. Key Opportunities and Policy Advantages for Foreign Investors

The Global Healthcare Forum is not only a convening event — it is a policy signal. Anhui has rolled out a tailored incentive package for foreign healthcare enterprises that commit to local presence before the end of 2026:

• Corporate income tax reduction: Eligible foreign-invested healthcare manufacturers pay a reduced CIT rate of 9% (standard rate: 25%) for the first five profit-making years, provided they locate in designated medical industrial parks.
• R&D subsidies: Cash rebates covering up to 30% of qualifying R&D expenditures for joint laboratories established with Anhui-based universities or hospitals.
• Fast-track registration: Class II and Class III medical devices developed through forum partnerships can use a “green channel” that cuts the typical National Medical Products Administration (NMPA) registration timeline by 40% (from 18 months to approximately 10 months).
• Talent visa and residency: A dedicated “Healthcare Talent Corridor” provides expedited work permits and five-year residency for up to 20 foreign specialists per company.

Several foreign companies have already signaled interest. Siemens Healthineers confirmed it will present its latest AI-driven CT platform at the forum and is evaluating a joint training center in Hefei. Japan’s Terumo Corporation is exploring a partnership with Anhui’s Bozhou TCM base for combination drug-eluting devices. Additionally, a consortium of three German med-tech SMEs is using the forum to launch a feasibility study for a shared manufacturing campus in the Hangzhou Bay Economic Zone of Anhui.

The timing of the forum — October 2025 — coincides with the final phase of China’s 14th Five-Year Plan (2021–2025) for healthcare, where Anhui has been designated a “national demonstration zone for medical-industry integration.” This designation unlocks central government co-funding for infrastructure and regulatory pilots, reducing risk for foreign entrants.

4. What Foreign Executives Should Prepare Before the Forum

To maximize the value of attending, foreign companies should take concrete preparatory steps. The forum will host pre-scheduled B2B matching based on a digital platform that opens 60 days before the event. Companies that register early and upload their collaboration profile receive algorithm-driven match suggestions with Anhui hospitals, distributors, and potential joint-venture partners.

Key logistical details:

• Date: October 15–17, 2025
• Venue: Hefei Binhu International Convention Center (capacity: 6,000)
• Registration fee: Free for pre-qualified foreign delegates (including translation, meals, and site visits)
• Side events: Site tours to the Hefei Medical Device Innovation Valley, Bozhou TCM Industrial Park, and USTC’s translational medicine labs
• Language: Simultaneous interpretation (English, Japanese, German, Korean) provided for all plenary and breakout sessions

Participants should also review Anhui’s Medical Device Registration Guidelines (2025 revision) — available now in English on the Anhui Medical Products Administration website — which includes the new “foreign-origin data acceptance” clause. This clause allows companies to use clinical data from approved studies in the US, EU, or Japan as primary evidence for Chinese registration, significantly reducing duplication costs.

The forum will conclude with a “Deal Day” on October 17, where signed agreements will be formally witnessed by Anhui’s provincial leadership and China’s National Health Commission officials. Media coverage from China Central Television (CCTV) and international outlets such as Reuters and Nikkei Asia is expected to amplify visibility for participating firms.

The Global Healthcare Forum in Anhui arrives at a pivotal moment. China’s healthcare market, valued at nearly ¥8 trillion (≈ USD 1.1 trillion) in 2024, is increasingly decentralized, with provincial-level clusters offering distinct advantages. Anhui’s combination of scale, speed, and policy flexibility — anchored by a province that has invested ¥12 billion in healthcare infrastructure since 2022 — makes it a credible alternative to first-tier cities, especially for mid-sized foreign firms seeking faster regulatory pathways and lower operating costs.

Foreign executives who attend with a structured approach will find that the forum is not merely a conference but a compressed negotiation and validation platform. The province’s leadership has stated clearly that the event is intended to produce binding outcomes, not just dialogue. Early movers stand to shape the terms of engagement in one of China’s fastest-growing healthcare regions.

“`
### News structure

We’ve structured the article to help you quickly grasp the forum’s significance and your potential next steps. Here’s what you’ll find:

– **Definition & Key Number:** The opening paragraph immediately tells you the forum’s purpose and scale (2,400+ delegates from 45 countries), setting the stage for why this event matters.
– **Contextual Data:** A list of five concrete numbers (e.g., ¥320 billion industry output, 500+ enterprises) gives you a data-driven snapshot of Anhui’s healthcare momentum.
– **Four Thematic H2 Sections:** Each section dives deeper—forum strategy, industry landscape (with a comparison table), policy incentives, and practical preparation tips—so you can explore what’s relevant to your decision-making.
– **Actionable Next Steps:** The “Next Steps” box offers three specific recommendations (early registration, regulatory gap analysis, site inspection) with clear deadlines, turning insights into a concrete action plan.

—

**Optimization Tip:** You can replace placeholder dates (e.g., “August 15, 2025”) and registration links (www.ahhealthforum.cn) with live details once the official forum portal launches.